SIREN : 840638902
GENNISIUM PHARMA is a French company founded 7 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in VITROLLES (13127), this company of category PME shows in 2024 a revenue of 1.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2018 |
|---|---|---|---|---|---|
| Revenue | 1 036 178 € | 569 604 € | 250 945 € | 49 470 € | N/C |
| Net income | -608 451 € | -853 379 € | -737 947 € | -624 700 € | -46 451 € |
| EBITDA | -570 722 € | -876 744 € | -777 131 € | -566 363 € | -46 451 € |
| Net margin | -58.7% | -149.8% | -294.1% | -1262.8% | N/C |
In 2024, GENNISIUM PHARMA achieves revenue of 1.0 M€. Over the period 2021-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +175.7%. Vs 2023, growth of +82% (570 k€ -> 1.0 M€). After deducting consumption (52 k€), gross margin stands at 984 k€, i.e. a rate of 95%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -571 k€, representing -55.1% of revenue. Positive scissor effect: EBITDA margin improves by +98.8 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -608 k€ (-58.7% of revenue), which will impact equity.
1 036 178 €
984 331 €
-570 722 €
-592 189 €
-608 451 €
-55.1%
The debt ratio (= Financial debt / Equity x 100) stands at 178%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 27%. The balance between equity and debt is satisfactory.
177.934%
26.594%
-58.842%
-0.892
20.5%
In 2024, the debt ratio of GENNISIUM PHARMA (177.93) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of GENNISIUM PHARMA (26.6%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2024, the repayment capacity of GENNISIUM PHARMA (-0.89) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 266.58. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
266.584
-3.035
In 2024, the liquidity ratio of GENNISIUM PHARMA (266.58) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of GENNISIUM PHARMA (-3.0x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 100 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 63 days. The gap of 37 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 65 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 146 days of revenue, i.e. 421 k€ to permanently finance.
421 414 €
100 j
63 j
65 j
146 j
Compare GENNISIUM PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of GENNISIUM PHARMA in 2024 is 1.0 M€.
GENNISIUM PHARMA recorded a net loss in 2024.
The headquarters of GENNISIUM PHARMA is located in VITROLLES (13127), in the department Bouches-du-Rhone.
The tax return of GENNISIUM PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
GENNISIUM PHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.